Antonio Pera Net Worth

The estimated Net Worth of Antonio R Pera is at least $2.08 Milione dollars as of 4 March 2024. Mr. Pera owns over 7,000 units of ANI Pharmaceuticals Inc stock worth over $1,446,379 and over the last 8 years he sold ANIP stock worth over $637,510. In addition, he makes $0 as Independent Director at ANI Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Pera ANIP stock SEC Form 4 insiders trading

Antonio has made over 3 trades of the ANI Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 7,000 units of ANIP stock worth $456,400 on 4 March 2024.

The largest trade he's ever made was selling 7,000 units of ANI Pharmaceuticals Inc stock on 4 March 2024 worth over $456,400. On average, Antonio trades about 619 units every 39 days since 2017. As of 4 March 2024 he still owns at least 26,627 units of ANI Pharmaceuticals Inc stock.

You can see the complete history of Mr. Pera stock trades at the bottom of the page.

Antonio Pera biography

Antonio Pera serves as Independent Director of the Company. Mr. Pera is a seasoned pharmaceutical industry leader with 40 years of experience. He retired as President of Par Pharmaceutical, the fifth-largest generic manufacturer in the United States, which is now part of Endo International, plc. Prior to Par, Mr. Pera held leadership positions at AmerisourceBergen, American Pharmaceuticals Partners, Bedford Laboratories, a division of Ben Venue Laboratories, and Baxter Healthcare.

How old is Antonio Pera?

Antonio Pera is 60, he's been the Independent Director of ANI Pharmaceuticals Inc since 2020. There are 4 older and 10 younger executives at ANI Pharmaceuticals Inc. The oldest executive at ANI Pharmaceuticals Inc is Thomas Penn, 73, who is the Independent Director.

What's Antonio Pera's mailing address?

Antonio's mailing address filed with the SEC is C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE, MN, 56623.

Insiders trading at ANI Pharmaceuticals Inc

Over the last 11 years, insiders at ANI Pharmaceuticals Inc have traded over $183,421,501 worth of ANI Pharmaceuticals Inc stock and bought 96,741 units worth $2,783,357 . The most active insiders traders include Arthur Przybyl, Venture Partners Ii Lp Meri... e Muthusamy Shanmugam. On average, ANI Pharmaceuticals Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,378,805. The most recent stock trade was executed by Meredith Cook on 13 August 2024, trading 250 units of ANIP stock currently worth $14,905.

What does ANI Pharmaceuticals Inc do?

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.

Complete history of Mr. Pera stock trades at ANI Pharmaceuticals Inc e Endo International plc

ANI Pharmaceuticals Inc executives and stock owners

ANI Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Robert Schrepfer,
  Senior Vice President - New Business Development and Specialty Sales
• Stephen Carey,
  Corporate Secretary, Vice President, Finance and Chief Financial Officer
• James Marken,
  Senior Vice President - Operations and Product Development
• James G. Marken,
  Sr. VP of Operations & Product Devel.
• Robert Brown,
  Independent Director
• Thomas Haughey,
  Independent Director
• Thomas Penn,
  Independent Director
• Patrick Walsh,
  Chairman of the Board
• David Nash,
  Independent Director
• Jeanne Thoma,
  Independent Director
• Antonio Pera,
  Independent Director
• Nikhil Lalwani,
  President, Chief Executive Officer, Director
• Muthasamy Shanmugam MS R.Ph.,
  Head of R&D and COO of Novitium Operations
• Ori Gutwerg,
  Sr. VP of Generics
• Christopher K. Mutz,
  Head of Rare Diseases
• Chad Gassert,
  Sr. VP of Corp. Devel. & Strategy
• Daniel Raynor,
  Director
• Arthur Przybyl,
  President and CEO
• Tracy Marshbanks,
  Director
• Fred Holubow,
  Director
• Peter A Lankau,
  Director
• Charlotte C. Arnold,
  Chief Financial Officer
• Renee P Tannenbaum,
  Director
• Ross J Mangano,
  Director
• Robert J. Jamnick,
  VP, Quality & Product Develop.
• Venture Partners Ii Lp Meri...,
  
• Ori Gutwerg,
  SVP, GENERICS
• Christopher Mutz,
  HEAD OF RARE DISEASE
• Krista Davis,
  SVP, CHIEF HR OFFICER
• Chad Gassert,
  SVP - CORP. DEV. & STRATEGY
• Meredith Cook,
  SR. VP, GENERAL COUNSEL & SEC.
• Muthusamy Shanmugam,
  HEAD OF R&D, COO-NOVITIUM OPS
• Matthew J Leonard,
  Director